Johns Hopkin’s researchers have created a PET-based approach that can direct cancer drugs to precise points in the brains of mice, according to a study published in the May 1 edition of the Journal of Nuclear Medicine. If proven effective in humans, the researchers believe their technique could help patients with difficult brain tumors, such as glioblastomas.
The prospective single-center study, published April 30 in the American Journal of Roentgenology, adds more weight to the growing literature suggesting PSMA-11’s vital role in prostate cancer management.
“With imaging, we’ll be able to identify vulnerable plaque, deliver treatment directly to it, and see whether the treatment is effective," said award recipient Yongjian Liu, PhD, with Washington University in St. Louis.
18F-DCFPyL PSMA PET/CT imaging accurately localized biochemically recurrent prostate cancer and prompted clinicians to change their management plans in more than 80% of patients, according to a recent study in the Journal of Nuclear Medicine.
The U.S. Department of Energy (DOE) recently transferred land in Oak Ridge, Tennessee, to Coquí Radio Pharmaceuticals, pushing the company closer to establishing a domestic production of Molybdenum-99 (Mo-99), an isotope used in many molecular imaging exams.
PET brain scans of living former NFL players with cognitive and neuropsychiatric symptoms showed higher tau levels than controls in brain regions typically affected by chronic traumatic encephalopathy (CTE), according to an April 11 study published in the New England Journal of Medicine (NEJM).
The American College of Radiology (ACR) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are collaborating to create a new clinical data registry to support high-quality practice and care in nuclear medicine.
Amyloid PET imaging greatly influenced the clinical management of patients with mild cognitive impairment (MCI) and dementia, according to the first phase of a multicenter trial published April 2 in JAMA.
PET/CT with the radiotracer 18F-FDG may have met its match at cancer detection in two new “FAPI” tracers based on gallium-68. The acronym stands for fibroblast activation protein inhibitor, and in a recent trial the new tracers equaled or bettered FDG PET/CT on image quality, required no fasting and yielded images in less time than FDG PET/CT.